Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Zyversa Therapeutics Inc ZVSA

Healthcare Biotechnology
ZyVersa Therapeutics, Inc. is a clinical-stage specialty biopharmaceutical company. The Company is focused on leveraging advanced technologies to develop drugs for patients with chronic renal or inflammatory diseases. Its lead renal drug candidate Cholesterol Efflux Mediator VAR 200 (2-hydroxypropyl-beta-cyclodextrin or 2HBCD) is in development to treat multiple renal indications. Its lead anti... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ZVSA)

ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes

GlobeNewswire April 4, 2024

ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire March 25, 2024

ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator(TM) VAR 200 in Patients with Diabetic Kidney Disease

GlobeNewswire March 18, 2024

ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled "Inflammation Illuminated,"at Benzinga's Virtual Healthcare Summit 2024 on March 20, 2024

GlobeNewswire March 14, 2024

ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity

GlobeNewswire February 29, 2024

ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100's Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications

GlobeNewswire February 28, 2024

ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option

GlobeNewswire February 22, 2024

ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases

GlobeNewswire February 14, 2024

ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the 2024 BIO CEO & Investor Conference to Provide Corporate Update and Discuss Key Milestones

GlobeNewswire February 7, 2024
View More News ››

Opinion & Analysis (NDAQ:ZVSA)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ZVSA)

ZVSA....Meh...it's a pig like all the others

Yesterday was just a "dead cat" bounce
Iseneschal - January 25, 2024

ZVSA...NR this a.m

On watch list...... recent previous runner on big Volume 64 cents
Iseneschal - January 24, 2024

ZVSA.....just like "clockwork"..hickory Dickory

Sub 60 pesos.....You've all been had ...again!
Iseneschal - January 18, 2024

ZVSA...This is what I'm thinking..and no..I have O position

This will probably get a last minute heroics on volume spike That will be the end of it This is a typical day watching the chasers get...
Iseneschal - January 17, 2024

Buh Bye

loser
Iseneschal - January 17, 2024

RE:ZVSA....whooop der id is

Seriously ....does anyone believe Mr. M's bs
Iseneschal - January 17, 2024
View more Bullboard ››

Royalties Inc.

Royalties Inc.

Royalties Inc. is focused on seeking cash flow generating royalty opportunities in various industries. While the Issuer’s ...
View More »